Abstract:The COVID‐19 pandemic caused by SARS‐CoV‐2 is threating global health. Inhibiting interaction of the receptor‐binding domain of SARS‐CoV‐2 S protein (S RBD) and human ACE2 receptor is a promising treatment strategy. However, SARS‐CoV‐2 neutralizing antibodies are compromised by their risk of antibody‐dependent enhancement (ADE) and unfavorably large size for intranasal delivery. To avoid the limitations of neutralizing antibodies, we proposed and demonstrated an aptamer blocking strategy by engineering aptamers' binding to the region on S RBD that directly mediates ACE2 receptor engagement, leading to block SARS‐CoV‐2 infection. With aptamer selection against S RBD and molecular docking, aptamer CoV2‐6 was identified and successfully applied to prevent, compete, and substitute ACE2 from binding to S RBD protein. CoV2‐6 was further shortened and engineered as a circular bivalent apamer CoV2‐6C3 (cb‐CoV2‐6C3) to improve the stability, affinity, and inhibition efficacy. With its circular form, cb‐CoV2‐6C3 aptamer was found to be stable in serum for more than 12 hours and can be stored at room temperature for more than 14 days. The circular bivalent aptamer binds to S RBD with high affinity (Kd of 0.13 nM) and blocks authentic SARS‐CoV‐2 virus with a half‐maximal inhibitory concentration of 0.42 nM. With its excellent affinity, stability, safety and programmability, our aptamer showed its capability to inhibit SARS‐CoV‐2 infection, suggesting aptamer blocking strategy as a new direction for developing therapeutic agents against COVID‐19 and other emerging infectious diseases.

Discovery of Aptamers Targeting Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein

Discovery of Aptamers Targeting the Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein

In-Silico Selection of Aptamer Targeting SARS-CoV-2 Spike Protein

Discovery of Novel Spike Inhibitors against SARS-CoV-2 Infection

A Multi-Faceted Binding Assessment of Aptamers Targeting the SARS-CoV-2 Spike Protein

Designing of peptide aptamer targeting the receptor-binding domain of spike protein of SARS-CoV-2: an in silico study

Broadly neutralizing aptamers to SARS-CoV-2: a diverse panel of modified DNA antiviral agents

COMPARISONS OF OBSERVATIONS AND SIMULATIONS OF THE MARS POLAR ATMOSPHERE

Nucleocapsid protein binding DNA aptamers for detection of SARS-COV-2

Aptamers targeting SARS-CoV-2 nucleocapsid protein exhibit potential anti pan-coronavirus activity

Aptamer Blocking Strategy Inhibits SARS‐CoV‐2 Virus Infection

Targeting Receptor Binding Domain and Cryptic Pocket of Spike glycoprotein from SARS-CoV-2 by biomolecular modeling

Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein

Identification of SARS-CoV-2-against aptamer with high neutralization activity by blocking the RBD domain of spike protein 1

Identification of hACE2-interacting sites in SARS-CoV-2 spike receptor binding domain for antiviral drugs screening

Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

Structures of the SARS-CoV-2 spike glycoprotein and applications for novel drug development

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

In silico analysis of SARS-CoV-2 proteins as targets for clinically available drugs

Screening and affinity optimization of single domain antibody targeting the SARS-CoV-2 nucleocapsid protein